Vernalis receives Roche milestone

Vernalis (LSE:VER) and Roche (SWX:ROCZ) chose a selective 5-HT2C receptor agonist as a lead clinical candidate from their 1999 research collaboration in obesity (see BioCentury Dec. 6, 1999). VER rec...